2023 iwCLL Program Agenda

This agenda has been prepared to provide information regarding the upcoming meeting and is subject to change.

Main Menu

Friday, October 6

7:30 AM

YIM Continental Breakfast

8:00 AM

Young Investigator Meeting

6:30 PM

iwCLL Welcome Reception

Saturday, October 7, 2023

7:15 AM

Continental Breakfast

8:15 AM

Welcome and Introductions

Jennifer Brown, MD, PhD

8:30 AM

Honoring the Past: In Memoriam and 20 Years of iwCLL 

Session 1: Integrative Aspects of Genomics

Session Co-Chairs: Christopher Oakes, MD, PhD & Gad A. Getz, PhD

 

8:40 AM

Multiomic Integration in CLL

Cynthia K. Hahn, MD

8:55 AM

Whole-Genome Analysis of CLL and Interplay of Coding, Non-Coding, Transcriptome and Epigenetic Events

Pauline Robbe, PhD

9:10 AM

Genomics of Richter Transformation: Part I

Ferran Nadeu, PhD

9:20 AM

Genomics of Richter Transformation: Part II

Erin Parry, MD, PhD

9:30 AM

Commentary on Each Other’s Work and Consensus Regarding the Genomics and Richter’s Transformation

Ferran Nadeu, PhD and Erin Parry, PhD

9:40 AM

Panel Discussion With Interactivity and Audience Q&A

9:50 AM

*SF3B1 mutation and ATM deletion co-drive leukemogenesis via centromeric R-loop dysregulation

Lili Wang, MD, PhD

10:00 AM

*Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia

Qu Jiang, PhD

10:10 AM

Morning Break

Session 2: Proteomics and Metabolism of CLL

Session Co-Chairs: Catherine Wu, MD & Jennifer Abelin, PhD

10:35 AM

Influence of Metabolism on Leukemia Progression

Matthew Vander Heiden, MD, PhD

10:50 AM

Proteogenomic Characterization of CLL and Drug Response/Resistance

Sascha Dietrich, MD

11:05 AM

CLL Proteomics and Immunoproteomics

Catherine Wu, MD

11:20 AM

*Targeting translation initiation as novel therapeutic in CLL

Etienne Moussay, PhD

11:30 AM

*METTL3 contributes to aggressive CLL via post-transcriptional regulation of splicing factor

Lili Wang, MD, PhD

11:40 AM

*TRAF3 inactivation in chronic lymphocytic leukemia enhances metabolic cellular plasticity through metabolic reprogramming and associates with adverse prognosis

Claudia Pérez Carretero, PhD

11:50 AM

Panel Discussion With Interactivity and Audience Q&A

12:05 PM

Lunch

12:55 PM

Industry Supported Symposium

Session 3: Microenvironment and Pre-Clinical Immunotherapies

Session Co-Chairs: Adrian Wiestner, MD, PhD & Silvia Deaglio, MD, PhD

1:55 PM

Anti-Tumor Immunity in the Lymphoid Microenvironment

Martina Seiffert, PhD

2:10 PM

The Tumor Supportive Microenvironment of CLL

Jérôme Paggetti, PhD

2:25 PM

Modeling the Tumor Microenvironment of CLL In Vitro

Cristina Scielzo, PhD

2:35 PM

The Tumor Microenvironment and Genetic Heterogeneity of CLL

Clare Sun, MD

2:45 PM

Panel Discussion With Interactivity and Audience Q&A

3:05 PM

*Constitutive VLA-4 activation is linked to BCR autonomous signaling in circulating CLL cells and promotes pro-survival signals through soluble blood-borne VCAM-1 binding

Erika Tissino, PhD

3:15 PM

*Exploiting the modulation of FOXO1 signaling as a therapeutic target in CLL through combination of ERK and BTK inhibition

Jodie F. Hay, PhD

3:25 PM

Afternoon Break

Session 4: Debate and Roundtable – How Do We Define Success in CLL?

Session Co-Chairs: John Seymour, MBBS, PhD & Lydia Scarfò, PhD

3:50 PM

*Does the Life Expectancy of Elderly CLL Patients Receiving Upfront Targeted Agents Approach the Life Expectancy of the General Population?

Stefano Molica, MD

4:00 PM

Multiparty “Statement of Perspective”

Michele Nadeem Baker
Danielle Brander, MD
Barbara Eichhorst, MD
Carsten Niemann, MD, PhD
William Wierda, MD, PhD 

4:35 PM

Panel Discussion With Interactivity and Audience Q&A

5:10 PM

iwCLL Update

Thomas J. Kipps, MD, PhD

5:25 PM

Adjourn

End of Day 1

* = Oral Presentation
** = Poster Presentation
*** = Late Breaker Poster Presentation

Sunday, October 8

7:15 AM

Continental Breakfast

Session 5: Optimizing Initial Therapy of CLL

Session Co-Chairs: Matthew Davids, MD, MMSc & Mazyar Shadman, MD, MPH

8:15 AM

The Role Today of Continuous BTK Inhibitors

Kerry Rogers, MD

8:30 AM

Updated Perspective on Time-Limited Venetoclax + Obinutuzumab

Othman Al-Sawaf, MD

8:45 AM

Current and Future Use of BTKi + BCL-2i Combinations

Nitin Jain, MD

9:00 AM

Panel Discussion With Interactivity and Audience Q&A

9:15 AM

Trials in Progress

9:15 AM

*Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group

Florian Simon, MD

9:25 AM

*Minimal residual disease-guided combination of ibrutinib and venetoclax compared to FCR in untreated patients with CLL of intermediate risk: interim results of MRD kinetics in the ERADIC trial from the FILO group

Anne-Sophie Michallet, MD, PhD

9:35 AM

*Bruton tyrosine kinase inhibitor ibrutinib induces hypertension by upregulating transcription of CaV1.2 calcium channel

Juejin Wang, MD, PhD

9:45 AM

*Stopping ibrutinib after 6 years of continuous exposure results in decreased or stable CLL levels for at least a year in most patients, providing further support for the STATIC trial evaluating intermittent BTKi treatment

Andy Rawstron, PhD

9:55 AM

Morning Break

10:20 AM

Industry Supported Symposium

Session 6: Mechanisms of Resistance

Session Co-Chairs: Jennifer Woyach, MD & Marek Mráz, PhD

11:20 AM

Resistance to Covalent BTKi

Adrian Wiestner, MD, PhD

11:35 AM

Resistance to Non-Covalent BTKi

Varsha Gandhi, MD

11:50 AM

Resistance to BCL2i

Rachel Thijssen, PhD

12:05 PM

*Bruton’s Tyrosine Kinase and Phospholipase C-Gamma 2 Mutational Profiles in Pooled Analysis of Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib

Inhye Ahn, MD

12:15 PM

*Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in Chronic Lymphocytic Leukemia (CLL)

Kiyomi Mashima, MD, PhD

12:25 PM

*Recurrent Genomic Alterations in the Apoptotic Machinery in Patients With CLL Treated With Venetoclax Monotherapy Following Treatment With BCRi

Jennifer Woyach, MD

12:35 PM

**Genomic Evolution and Resistance to Pirtobrutinib in Covalent BTK-Inhibitor Pre-treated Chronic Lymphocytic Leukemia Patients: Results from the Phase I/II BRUIN Study

Jennifer Brown, MD, PhD

12:40 PM

Panel Discussion With Interactivity and Audience Q&A

12:55 PM

Lunch

1:45 PM

Industry Supported Symposium

Session 7: Future Directions for the Treatment of Relapsed/Refractory CLL

Session Co-Chairs: Arnon Kater, MD, PhD & Danielle Brander, MD

2:45 PM

*Epcoritamab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results From the Phase 1b/2 EPCORE CLL-1 Trial Expansion Cohort

Arnon Kater, MD, PhD

2:55 PM

*Bendamustine, Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL): Updated Results of the CLL2-BAAG Trial of the German CLL Study Group (GCLLSG)

Paula Cramer, MD

3:05 PM

**Final 7-year Follow Up and Retreatment Substudy Analysis of MURANO: Venetoclax-Rituximab-Treated Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

John F. Seymour, MBBS, FRACP, PhD

3:10 PM

**Lisocabtagene maraleucel (liso-cel) in R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): primary analysis of TRANSCEND CLL 004

Tanya Siddiqi, MD

3:15 PM

BTK Degraders – From Bench To Bedside

Alexey Danilov, MD, PhD

3:25 PM

Novel Inducers of Apoptosis

Deepa Sampath, PhD

3:35 PM

How to Overcome T-Cell Dysfunction: Bispecifics

Arnon Kater, MD, PhD

3:45 PM

How to Overcome T-Cell Dysfunction: Cellular Therapies

Jos Melenhorst, PhD

3:55 PM

Panel Discussion with Interactivity and Audience Q&A

4:10 PM

Binet/Rai Medal Presentation

4:20 PM

General Session Adjourns

4:30 PM

Wine & Cheese Poster Session and Reception

* = Oral Presentation
** = Poster Presentation
*** = Late Breaker Poster Presentation

End of Day 2

Monday, October 9

7:15 AM

Continental Breakfast

Session 8: Richter Transformation – From Biology to Clinic

Session Co-Chairs: Inhye Ahn, MD & Lili Wang, MD, PhD

8:15 AM

In Vivo Modeling of CLL Transformation: PDX Model

Silvia Deaglio, MD, PhD

8:25 AM

In Vivo Modeling of CLL Transformation: Multiplex In Vivo CRISPR Editing

Elisa ten Hacken, PhD

8:35 AM

In Vivo Modeling of CLL Transformation: TP53 and CDKN2a/b Model

Dimitar Efremov, MD, PhD

8:45 AM

Panel Discussion on In Vivo Modeling

8:55 AM

*Mitochondrial dysregulation and metabolite imbalance in Richter Transformation: Insights from a mouse model

Prajish S. Iyer, PhD

9:05 AM

*Sequencing of circulating tumour DNA reveals additional driver mutations in Richter Transformation

Niamh Appleby, MRCPI FRCPath

9:10 AM

***Chronic lymphocytic leukemia patient-derived xenografts recapitulate clonal evolution to Richter Transformation

Heribert Playa-Albinyana, BSc, MSc

9:15 AM

Chemoimmunotherapy and BCR-Targeted Agents for Richter Transformation

Sameer Parikh, MBBS

9:25 AM

Investigational Therapies for Richter Transformation: Bispecifics

Philip Thompson, MBBS

9:35 AM

Investigational Therapies for Richter Transformation: Cellular Therapies

Tanya Siddiqi, MD

9:45 AM

Panel Discussion with Interactivity and Audience Q&A

9:55 AM

Morning Break

Session 9: Immunodeficiency and Infections in Patients with CLL

Session Co-Chairs: Carsten Niemann, MD, PhD & Clare Sun, MD

10:15 AM

General Management of CLL patients from a Vaccine and Prophylaxis Standpoint

Carolyn Owen, MD

10:30 AM

What Can We Learn from COVID-19 About Immune Dysfunction and Risk of Infections in CLL?

Yair Herishanu, MD

10:45 AM

CLL Vaccine Responsiveness

Chris Pleyer, MD

11:00 AM

Panel Discussion with Interactivity and Audience Q&A

11:15 AM

*Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with targeted drugs: pooled analysis of clinical trials from the German CLL Study Group (GCLLSG)

Elia Boccellato, MD

11:25 AM

*Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia

Randall S. Davis, MD

11:35 AM

Industry Supported Symposium

12:35 PM

Lunch

1:25 PM

Keynote Anticipated Role of AI/Machine Learning in Research and Treatment of CLL and Other Malignancies

Mihaela van der Schaar, PhD

 

Session 10: Global Perspective on CLL Management – Real World Data and Patient Experiences

Session Co-Chairs: Anna Schuh, MD, PhD & Pat Garcia-Gonzalez

1:55 PM

Special Announcement From the iwCLL

Anna Schuh, MD, PhD

2:00 PM

The Impact of the War on Management of Patients with CLL in Ukraine: What can the iwCLL do to Mitigate Impact in Short and Longer Term

Iryna Kriachok, PhD

2:10 PM

Managing Patients with CLL from Different Socio-Economic Backgrounds in Argentina

Miguel Pavlovsky, MD

2:20 PM

Update on the iwCLL Capacity Building Pilot Program in Tanzania

William Frank Mawalla, MD

2:30 PM

Challenges of Diagnosis and Management of Patients with CLL in South Korea

Ja Min Byun, MD, PhD

2:40 PM

Trial Updates from China

Shenmiao Yang, MD

2:50 PM

Global Survey Results from the CLL Advocates Network

Brian Koffman, MDCM (retired), DCFP, FCFP, DABFP, MSEd

3:00 PM

*A high proportion of IGHV4-39, subset #8 and #8B in Chinese patients with chronic lymphocytic leukemia: a retrospective analysis of 3154 Ig VH sequences by cwCLL, Chinese workshop on CLL

Yi Xia, MD

3:10 PM

Panel Discussion With Interactivity and Audience Q&A

3:25 PM

Afternoon Break

Session 11: Past, Present, and Future of CLL

Session Chair: Jennifer R. Brown, MD, PhD

3:50 PM

Future Research Priorities and Unmet Needs in CLL: A Roundtable Discussion and Audience Q&A

Jennifer R. Brown, MD, PhD
Florence Cymbalista, MD, PhD
Matthew Davids, MD, MMSc
Paolo Ghia, MD, PhD
Thomas J. Kipps, MD, PhD
Susan O’Brien, MD

4:55 PM

Closing Comments/iwCLL 2023 Awards/2025 Announcement

Jennifer R. Brown, MD, PhD

5:10 PM

Close of Workshop

* = Oral Presentation
** = Poster Presentation
*** = Late Breaker Poster Presentation